Panbela Therapeutics Inc. (OTCQB: PBLA) Stock Sees Sell-Off: Should You Panic?
The clinical stage company involved in the development of disruptive therapeutics meant for addressing the urgent unmet medical needs of patients was in focus yesterday. Panbela Therapeutics Inc. (OTCQB: PBLA) saw its stock suffer from a selloff and record a decline of 7%.
However, it should be noted that yesterday the company announced that it had been successful in enrolling the first patient in the Phase 1 dose escalation study for one of its products.
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
The product in question was the CPP IX S in the treatment of STK11 mutant NSCLC (non-small cell lung cancer). The first aim of the trial would be to find out the maximum tolerated dose of the product in combination with Keytruda, an immune checkpoint inhibitor. Once that is completed, the trial would move on to Phase II.
The data collected from the Phase I trial would be available by the middle of 2025, while the Phase II of the trial would begin at some point in 2024. It was also noted that there was a significant necessity for combining new agents with the standard products used in the field of immunotherapy in order to overcome the lower levels of anti-tumor T cells.
Key Quote
“Options for combining new agents with standard of care immunotherapy are critical to overcoming the reduced levels of anti-tumor T cells and immune evasion that are observed in STK11 mutant tumors,” said Jhanelle Gray, M.D., Principal Investigator of the clinical trial, Chair of Moffitt’s Department of Thoracic Oncology, and Co-Leader of Moffitt’s Molecular Medicine Program. “By working with Panbela, we are using CPP-1X-S to modulate polyamine levels and potentially restimulate the immune system, which may be a valuable therapeutic strategy to target these hard-to-treat tumors.”
Traders Notes
| +/- EMA(20) | 0.35 (-2.86%) |
| +/- SMA(50) | 0.35 (-2.86%) |
| +/- SMA(200) | 2.59 (-86.87%) |
| 5-Day Perf. | +2.97% |
| 1-Month Perf. | -1.45% |
| 3-Month Perf. | -11.69% |
| 6-Month Perf. | -46.88% |
| YTD Perf. | -98.14% |
| 1-Year Perf. | -98.64% |
| RSI(14) | 47.87 |
| ATR(14) | 0.04 |
| ADX(14) | 40.83 |
| Beta (5Y) | 2.80 |
